Literature DB >> 20118979

Targeted therapies: tailored treatment for ovarian cancer: are we there yet?

Cristiana Sessa, Gianluca Del Conte.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20118979     DOI： 10.1038/nrclinonc.2009.233

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?

Authors:  Stanley B Kaye
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

Review 2.  Angiogenesis as a strategic target for ovarian cancer therapy.

Authors:  Whitney A Spannuth; Anil K Sood; Robert L Coleman
Journal:  Nat Clin Pract Oncol       Date:  2008-02-12

3.  Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

Authors:  Limin Hu; Judith Hofmann; Yiling Lu; Gordon B Mills; Robert B Jaffe
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

4.  Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Authors:  Stephen A Cannistra; Ursula A Matulonis; Richard T Penson; Julie Hambleton; Jakob Dupont; Howard Mackey; Jeffrey Douglas; Robert A Burger; Deborah Armstrong; Robert Wenham; William McGuire
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

5.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

Review 6.  Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2008-04       Impact factor: 2.762

Review 7.  Hallmarks of 'BRCAness' in sporadic cancers.

Authors:  Nicholas Turner; Andrew Tutt; Alan Ashworth
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

8.  A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer.

Authors:  Y Watanabe; M Koi; H Hemmi; H Hoshai; K Noda
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

9.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245
  9 in total
  1 in total

1.  Combining portable Raman probes with nanotubes for theranostic applications.

Authors:  Ashwinkumar A Bhirde; Gang Liu; Albert Jin; Ramiro Iglesias-Bartolome; Alioscka A Sousa; Richard D Leapman; J Silvio Gutkind; Seulki Lee; Xiaoyuan Chen
Journal:  Theranostics       Date:  2011-07-04       Impact factor: 11.556
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.